| Patient | Elizabeth Barrett Browning |
|---|---|
| Date of birth | 1987-03-06 |
| Identifiers | MRN HR-NI026-SYN; SSN (made up) 000-26-4157 |
| Document date | 2026-04-20 |
| Author | Clementine Haverford-Asante, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week review: cultures, airway clearance, bone density, grief therapy, and the opioid dose. [S]
Ms. Barrett Browning returns four weeks after the consultation. She does airway clearance every morning and evening and finds it tiring but worth it: her sputum is down from about four to two tablespoons a day, and she has seen no blood for two weeks. She has had four grief therapy sessions by video and says it is the first time she has spoken of her brother aloud; the first two sessions were very hard. She sleeps a little better. She had her DXA scan last week. She asks whether she could try a lower morphine dose, now that the cough is easing and she is sleeping a little better, but she does not want to stop it and is afraid of the restlessness she remembers when a dose was late. [S]
| Element | Detail |
|---|---|
| Airway clearance | Twice daily; sputum down to two tablespoons a day; no blood for two weeks |
| Mycobacterial cultures | No growth at four weeks |
| Grief therapy | Four sessions |
| Her request | A slow, small reduction in morphine |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; a little more energy |
| Respiratory | Positive | Cough with two tablespoons of sputum a day; no blood |
| Gastrointestinal | Positive | Stools every two days; no pain |
| Psychiatric | Positive | Grief still heavy but more bearable; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Morphine sulfate 2 mg/mL oral solution, 5 mL (10 mg) by mouth twice daily, morning and bedtime (20 mg a day; long-standing prescription, continued) | 5 mL (10 mg) twice daily, morning and bedtime | Oral route | 2019-03-01 to 2026-04-19 | completed | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911 | As needed for suspected overdose; keep two devices at home | Nasal route | 2026-03-16 | active | S |
| Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth daily | Two tablets daily | Oral route | 2026-03-16 | active | S |
| Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day) | 4.5 mL (9 mg) twice daily, morning and bedtime | Oral route | 2026-04-20 to 2026-06-14 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 157 | cm | S |
| 2026-04-20 | Body weight | 42.4 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 17.2 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 88 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 36.7 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | DXA Lumbar spine [Z-score] Bone density | -1.4 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-04-20 | DXA Femur [Z-score] Bone density | -1.1 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-04-20 | C reactive protein [Mass/volume] in Serum or Plasma | 4.1 | mg/L | <=5 mg/L | Normal | S |
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 10 | {score} | S |
Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Brighter; weight 42.4 kg |
| Respiratory | Fewer crackles at the left base; no wheeze |
| Neurological | Not drowsy; pupils normal size |
| Psychiatric | Engaged; tearful briefly when speaking of her brother; no suicidal ideation |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with daily yellow sputum, occasional streaks of blood, and breathlessness on stairs, worse in winter, for several years after an illness with blood in the sputum about eight years ago; tuberculosis, nontuberculous mycobacteria and bronchiectasis to be distinguished | resolved | confirmed | R05.3 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; it echoes her documented chest illness (D). |
| Non-cystic fibrosis bronchiectasis of the left lower lobe and lingula with chronic Haemophilus influenzae infection and mild airflow obstruction (Bronchiectasis Severity Index 3, mild); tuberculosis and nontuberculous mycobacterial disease excluded; synthetic modern diagnosis chosen for a historical chest illness whose cause is disputed | active | confirmed | J47.9 | S — Synthetic modern diagnosis; the nature of her historical chest illness remains undetermined (R, disputed). |
| Long-term prescribed opioid therapy (oral morphine 20 mg a day for many years, for cough, sleeplessness and palpitations), with expected physiological dependence; no opioid use disorder on DSM-5-TR assessment | active | confirmed | Z79.891 | S — Synthetic modern problem anchored to her documented prescribed opium (D); tolerance and withdrawal on prescribed opioids do not count toward opioid use disorder. |
| Prolonged grief disorder after the drowning of her closest brother five years ago, with yearning, self-blame, avoidance of reminders of the sea, and depressive symptoms (PHQ-9 12); no suicidal ideation | active | confirmed | F43.81 | S — Synthetic modern diagnosis anchored to her documented bereavement (D); not a claim about her real mental health. |
| Vitamin D deficiency (25-hydroxyvitamin D 15 ng/mL) in a woman who rarely goes outdoors | active | confirmed | E55.9 | S — Synthetic finding at intake; repleted by twelve weeks. |
| Underweight (BMI 16.8) with a small appetite | active | confirmed | R63.6 | S — Synthetic finding at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Mycobacterial culture including nontuberculous mycobacteria | At diagnosis (final at six to eight weeks), then yearly and with unexplained decline | Ordered | No growth at four weeks; final at eight weeks |
| Laboratory | Sputum bacterial culture | At each review and at every exacerbation, before antibiotics | Completed today | Light growth of Haemophilus influenzae; no Pseudomonas |
| Laboratory | C-reactive protein | With symptoms or exacerbation | Completed today | 4.1 mg/L, from 8.4 |
| Self-management | Airway clearance technique and exercise | Every visit | Completed today | Twice daily with the oscillating PEP device; technique checked by the physiotherapist last week |
| Self-management | Exacerbations: number in the past year, written plan, and rescue antibiotic | Every visit | Completed today | None since diagnosis; plan and antibiotic at home |
| Self-management | Hemoptysis: amount, and when to seek emergency care | Every visit | Completed today | No blood for two weeks |
| Medication safety | Opioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goals | Every visit, and at least every three months | Completed today | No sedation; cough and sleep improving; she chose a reduction |
| Medication safety | Prescription drug monitoring program check | With every prescription, and at least every three months | Completed today | One prescriber, one pharmacy |
| Medication safety | Naloxone at home, and no benzodiazepines or other sedatives | Every visit | Completed today | Naloxone at home; no sedatives |
| Medication safety | Opioid use disorder assessment (DSM-5-TR) | At review and whenever there is concern; tolerance and withdrawal on prescribed use do not count | Completed today | No criteria met apart from tolerance and withdrawal, which do not count on prescribed use |
| Survey | PHQ-9 | At least monthly during active treatment (CMID) | Completed today | 10, from 12 |
| Examination | Suicide risk review and safety plan | Every visit | Completed today | No suicidal ideation; plan current |
| Self-management | Grief therapy attendance and response | Weekly for sixteen sessions | Completed today | Four sessions attended |
| Imaging | Bone density (DXA) | Once, for risk factors; repeat only if risk changes | Completed today | Spine Z -1.4, femoral neck Z -1.1: within the expected range |
| Laboratory | 25-hydroxyvitamin D | Twelve weeks after starting replacement, then yearly; target 30 ng/mL or more (CMID) | Due | 15 ng/mL at intake; recheck at twelve weeks |
| Examination | Weight and BMI | Every visit | Completed today | 42.4 kg, BMI 17.2, up 0.9 kg |
Goal progress:
Guideline basis: British Thoracic Society Guideline for Bronchiectasis in Adults (2019); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR): opioid use disorder and prolonged grief disorder criteria (2022); Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026)
Follow-up: Three-month review with the final mycobacterial cultures, vitamin D, PHQ-9 and GAD-7, and a check on the first dose step. Emergency care for more than a few teaspoons of blood. Next scheduled visit 2026-06-15: three-month review: final mycobacterial cultures, vitamin D, mood, safety, and the opioid dose. [S]